4sm Search Results


two stage voltage amplifier  (Mini-Circuits)
93
Mini-Circuits two stage voltage amplifier
Two Stage Voltage Amplifier, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/two stage voltage amplifier/product/Mini-Circuits
Average 93 stars, based on 1 article reviews
two stage voltage amplifier - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
handflex cable  (Mini-Circuits)
93
Mini-Circuits handflex cable
Handflex Cable, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/handflex cable/product/Mini-Circuits
Average 93 stars, based on 1 article reviews
handflex cable - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
minicircuits era 1sm  (Mini-Circuits)
93
Mini-Circuits minicircuits era 1sm
Minicircuits Era 1sm, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/minicircuits era 1sm/product/Mini-Circuits
Average 93 stars, based on 1 article reviews
minicircuits era 1sm - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
4sm xmu-mp-1  (ApexBio)
90
ApexBio 4sm xmu-mp-1
a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, <t>FPH2</t> and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)
4sm Xmu Mp 1, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/4sm xmu-mp-1/product/ApexBio
Average 90 stars, based on 1 article reviews
4sm xmu-mp-1 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
4sm  (AAALAC International Inc)
90
AAALAC International Inc 4sm
a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, <t>FPH2</t> and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)
4sm, supplied by AAALAC International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/4sm/product/AAALAC International Inc
Average 90 stars, based on 1 article reviews
4sm - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
4sm  (ApexBio)
90
ApexBio 4sm
a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with <t>4SM</t> from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)
4sm, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/4sm/product/ApexBio
Average 90 stars, based on 1 article reviews
4sm - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
factor distribution of zk60-4sm alloy  (Schmid GmbH)
90
Schmid GmbH factor distribution of zk60-4sm alloy
a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with <t>4SM</t> from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)
Factor Distribution Of Zk60 4sm Alloy, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/factor distribution of zk60-4sm alloy/product/Schmid GmbH
Average 90 stars, based on 1 article reviews
factor distribution of zk60-4sm alloy - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
disposable syringe filter unit frisenette 4- sm-16555 k  (Frisenette ApS)
90
Frisenette ApS disposable syringe filter unit frisenette 4- sm-16555 k
a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with <t>4SM</t> from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)
Disposable Syringe Filter Unit Frisenette 4 Sm 16555 K, supplied by Frisenette ApS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/disposable syringe filter unit frisenette 4- sm-16555 k/product/Frisenette ApS
Average 90 stars, based on 1 article reviews
disposable syringe filter unit frisenette 4- sm-16555 k - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
interpolation option interpol 1/4 sm  (SAS institute)
90
SAS institute interpolation option interpol 1/4 sm
a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with <t>4SM</t> from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)
Interpolation Option Interpol 1/4 Sm, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/interpolation option interpol 1/4 sm/product/SAS institute
Average 90 stars, based on 1 article reviews
interpolation option interpol 1/4 sm - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)

Journal: Emerging Microbes & Infections

Article Title: Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection

doi: 10.1038/s41426-018-0143-9

Figure Lengend Snippet: a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)

Article Snippet: The 4SM was purchased from APExBIO, USA (FH1, B3700; FPH1, B3701; FPH2, B4753; XMU-MP-1, A8735).

Techniques:

a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)

Journal: Emerging Microbes & Infections

Article Title: Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection

doi: 10.1038/s41426-018-0143-9

Figure Lengend Snippet: a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)

Article Snippet: The 4SM was purchased from APExBIO, USA (FH1, B3700; FPH1, B3701; FPH2, B4753; XMU-MP-1, A8735).

Techniques:

a Investigation of the optimized 2-week hepatic differentiation procedure including 4SM treatment and enrichment of precursor HLCs (DP pdHepaRG). b Classic 4-week hepatic differentiation procedure with only DMSO treatment

Journal: Emerging Microbes & Infections

Article Title: Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection

doi: 10.1038/s41426-018-0143-9

Figure Lengend Snippet: a Investigation of the optimized 2-week hepatic differentiation procedure including 4SM treatment and enrichment of precursor HLCs (DP pdHepaRG). b Classic 4-week hepatic differentiation procedure with only DMSO treatment

Article Snippet: The 4SM was purchased from APExBIO, USA (FH1, B3700; FPH1, B3701; FPH2, B4753; XMU-MP-1, A8735).

Techniques:

a Schematic diagram of the experimental plan for engraftment of HepaRG cells in different hepatic differentiation states to liver failure FRGS mice with or without 4SM treatment. FRGS mice without engraftment were used as a control. b ELISA assays to determine the serum hALB levels at weeks 0 to 24 post-engraftment ( n = 6/group). c FACS analysis to examine the ratio of hALB + cells in the liver of the engrafted FRGS mice with 4SM treatment at weeks 8 and 24 after engraftment. FRGS mice without cell engraftment were used as a control ( n = 6/group). d qRT-PCR to detect the mRNA levels of control (hGAPDH) or nine typical human hepatocyte-specific genes in hALB + cells from the engrafted FRGS mice treated with 4SM at week 8 and 24 after engraftment ( n = 3/group). e IHC to visualize hALB-positive cells in liver tissues from the engrafted FRGS mice with 4SM treatment at week 24 post-engraftment (bar = 200 μm). (* P < 0.01; ** P < 0.001; **** P < 0.00001; NS no significant difference, U.D. undetectable)

Journal: Emerging Microbes & Infections

Article Title: Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection

doi: 10.1038/s41426-018-0143-9

Figure Lengend Snippet: a Schematic diagram of the experimental plan for engraftment of HepaRG cells in different hepatic differentiation states to liver failure FRGS mice with or without 4SM treatment. FRGS mice without engraftment were used as a control. b ELISA assays to determine the serum hALB levels at weeks 0 to 24 post-engraftment ( n = 6/group). c FACS analysis to examine the ratio of hALB + cells in the liver of the engrafted FRGS mice with 4SM treatment at weeks 8 and 24 after engraftment. FRGS mice without cell engraftment were used as a control ( n = 6/group). d qRT-PCR to detect the mRNA levels of control (hGAPDH) or nine typical human hepatocyte-specific genes in hALB + cells from the engrafted FRGS mice treated with 4SM at week 8 and 24 after engraftment ( n = 3/group). e IHC to visualize hALB-positive cells in liver tissues from the engrafted FRGS mice with 4SM treatment at week 24 post-engraftment (bar = 200 μm). (* P < 0.01; ** P < 0.001; **** P < 0.00001; NS no significant difference, U.D. undetectable)

Article Snippet: The 4SM was purchased from APExBIO, USA (FH1, B3700; FPH1, B3701; FPH2, B4753; XMU-MP-1, A8735).

Techniques: Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR